★ Click "Listen to the full article" above to free your hands
Author: Yang Ruixu, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Science and Technology Innovation 2030 - "Research on the Prevention and Treatment of Cancer, Cardiovascular and Cerebrovascular, Respiratory and Metabolic Diseases" major project, focusing on the key issues of disease prevention and control, adhering to demand-oriented and problem-oriented, and in an open competition and directional merit-based manner, the Science and Technology Development Center of the National Health Commission launched 75 key research directions in November 2023, focusing on solving the problems of prevention, diagnosis and treatment of major diseases such as cancer, cardiovascular and cerebrovascular, respiratory and metabolic diseases, insisting on paying equal attention to traditional Chinese and Western medicine, and centering on the formation of a "Chinese plan" for the prevention and treatment of chronic diseases Deploy research and research on relevant pathogenesis, screening technology, clinical diagnosis and treatment, demonstration and promotion, etc.
Metabolic-associated fatty liver disease (MAFLD/MASLD), also known as nonalcoholic fatty liver disease, is the most common chronic progressive liver disease in mainland China, which is closely related to the high incidence of cardiovascular-renal-metabolic syndrome and hepatic and non-hepatic malignant tumors, and seriously endangers national health. However, the diagnostic criteria for MAFLD are not unified worldwide, and the classification and staging still rely on pathological evaluation of liver biopsy, and the characteristics, mechanisms and predictors of the prognosis of liver and extrahepatic diseases in MAFLD patients are still unclear.
To this end, the Medical and Health Science and Technology Development Research Center of the National Health Commission has included MAFLD, along with obesity, diabetes, and metabolic syndrome, among the metabolic diseases that need to be tackled urgently in the 2023 National Science and Technology Major Project. In November 2023, the "Clinical Classification and Precision Intervention Study on Metabolic-related Fatty Liver Disease (Clinical Research)" will set up one young scientist project and one major project in parallel by open competition, and open to clinical experts across the country to apply freely.
In September 2024, Professor Fan Jiangao from Xinhua Hospital affiliated to Shanghai Jiao Tong University School of Medicine led the application for the "Precise Intervention Study Based on Clinical Classification and Outcomes of Metabolism-related Fatty Liver Disease" as the project leader, which stood out among many application projects, and successfully obtained the project approval and submitted the project task book after multiple rounds of review. Project No.: 2023ZD0508700, the project implementation period is from August 2024 to July 2028, and the project funding includes 14.7 million yuan from the central government.
The project "Precise Intervention Research Based on Clinical Classification and Outcomes of MAFLD" set up 5 topics, which were respectively led by Professor Fan Jiangao, Director of the Department of Gastroenterology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine (based on the establishment of risk prediction models for different outcomes of MAFLD in the cohort population), Professor You Hong, Vice President of Beijing Friendship Hospital Affiliated to Capital Medical University (establishment of clinical classification and prognosis evaluation system for MAFLD based on liver biopsy), and Chief Physician Bian Hua, Department of Endocrinology, Zhongshan Hospital, Fudan University ( Fatty liver disease and metabolic disorders interaction and mechanism), Professor Shi Junping, Director of the Medical Department of Hangzhou Normal University (digital therapy and clinical trials of new drugs for MAFLD precision intervention), and Professor Wang Li of the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (establishment of MAFLD big data platform and development of artificial intelligence diagnosis and evaluation technology) as project leaders, Professor Li Xiaoying of Fudan University and Professor Huang Weishen of Hong Kong Chinese University are the project consultants and backbones.
The main members (backbone) of the project include Professor Li Yiling from the First Affiliated Hospital of China Medical University, Professor Zhang Jing from Beijing You'an Hospital, Zhao Jingjie, Deputy Director of Beijing Friendship Hospital, Xu Liang, President of Tianjin Second People's Hospital, Chen Shuohua, Director of Kailuan General Hospital, Chen Yi, Deputy Director of the First Affiliated Hospital of Zhejiang University School of Medicine, Professor Zheng Qi from the First Affiliated Hospital of Fujian Medical University, Professor Xie Qing from Shanghai Ruijin Hospital, Professor Huang Lihong from Chinese University of Hong Kong, Dr. Shao Jinhua, General Manager of Wuxi Haskell Medical Technology Co., Ltd., and Keskai ( Prof. Xu Huaqiang, Institute of Materia Medica, Chinese Academy of Sciences, Ms. Zhang Junhui, General Manager of Chongqing Huiren Health Management Co., Ltd., and Prof. Chao Sun, Xianting Jiao, Ruixu Yang, Xin Sun and Qing Su from Shanghai Xinhua Hospital.
The purpose of this project is to obtain multi-level omics data of MAFLD patients at different stages through multi-center clinical studies, and to construct and validate non-invasive models for MAFLD classification and staging, as well as biomarkers for predicting the risk and treatment response of different outcomes. Led the completion of a large-sample long-course prospective randomized controlled study to develop digital therapy software and new drugs; Establish a big data platform and intelligent management system for MAFLD patient information; High-level evidence-based evidence was used to formulate a precise diagnosis and treatment plan based on the scientific classification and staging of MAFLD, and the standardized management rate of MAFLD in mainland China was increased by more than 20%.
The successful approval of this project has received strong support from many experts, professors and relevant leaders and staff, and we would like to express our heartfelt thanks and sincere respect! The smooth progress of the project still needs more guidance and cooperation from everyone!
Source: Hepatobiliary Photography Platform